203 related articles for article (PubMed ID: 18496682)
1. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients.
Bohanec Grabar P; Rozman B; Tomsic M; Suput D; Logar D; Dolzan V
Eur J Clin Pharmacol; 2008 Sep; 64(9):871-6. PubMed ID: 18496682
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Bohanec Grabar P; Grabnar I; Rozman B; Logar D; Tomsic M; Suput D; Trdan T; Peterlin Masic L; Mrhar A; Dolzan V
Drug Metab Dispos; 2009 Oct; 37(10):2061-8. PubMed ID: 19581389
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.
Wiese MD; Schnabl M; O'Doherty C; Spargo LD; Sorich MJ; Cleland LG; Proudman SM
Arthritis Res Ther; 2012 Jul; 14(4):R163. PubMed ID: 22784880
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis.
Soukup T; Dosedel M; Nekvindova J; Toms J; Vlcek J; Pavek P
Clin Exp Rheumatol; 2015; 33(3):426-32. PubMed ID: 25664505
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.
Hopkins AM; Wiese MD; Proudman SM; O'Doherty CE; Upton RN; Foster DJ
Br J Clin Pharmacol; 2016 Jan; 81(1):113-23. PubMed ID: 26331989
[TBL] [Abstract][Full Text] [Related]
6. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis.
Grabar PB; Rozman B; Logar D; Praprotnik S; Dolzan V
Ann Rheum Dis; 2009 Aug; 68(8):1367-8. PubMed ID: 19605743
[No Abstract] [Full Text] [Related]
7. The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity.
Hopkins AM; O'Doherty CE; Foster DJ; Suppiah V; Upton RN; Spargo LD; Cleland LG; Proudman SM; Wiese MD
J Clin Pharm Ther; 2014 Oct; 39(5):555-60. PubMed ID: 25040563
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics.
Saiz-Rodríguez M; Ochoa D; Belmonte C; Román M; Vieira de Lara D; Zubiaur P; Koller D; Mejía G; Abad-Santos F
J Psychopharmacol; 2019 Apr; 33(4):522-531. PubMed ID: 30789308
[TBL] [Abstract][Full Text] [Related]
9. The association between CYB5A gene rs1790834 polymorphism and clinical improvement after 6 months of leflunomide treatment in women with rheumatoid arthritis.
Machaj F; Rosik J; Szostak B; Malinowski D; Safranow K; Olędzka G; Wiechec E; Pawlik A
Clin Rheumatol; 2023 Sep; 42(9):2477-2483. PubMed ID: 37289314
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements.
Saraeva RB; Paskaleva ID; Doncheva E; Eap CB; Ganev VS
J Clin Pharm Ther; 2007 Dec; 32(6):641-9. PubMed ID: 18021343
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.
Laika B; Leucht S; Heres S; Schneider H; Steimer W
Pharmacogenomics J; 2010 Feb; 10(1):20-9. PubMed ID: 19636338
[TBL] [Abstract][Full Text] [Related]
12. Frequency and impact of DHODH, ABCG2 and CYP2C19 SNPs on the therapeutic efficacy, tolerability and toxicity of leflunomide.
Makarem YS; Hareedy MS; Hassanien M; Ahmed EA; Hetta HF; Mohamed AA
Pharmacogenomics; 2021 Dec; 22(18):1201-1209. PubMed ID: 34747629
[No Abstract] [Full Text] [Related]
13. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
Jaquenoud Sirot E; Knezevic B; Morena GP; Harenberg S; Oneda B; Crettol S; Ansermot N; Baumann P; Eap CB
J Clin Psychopharmacol; 2009 Aug; 29(4):319-26. PubMed ID: 19593168
[TBL] [Abstract][Full Text] [Related]
14. CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.
Czerwensky F; Leucht S; Steimer W
Ther Drug Monit; 2015 Apr; 37(2):152-60. PubMed ID: 25090458
[TBL] [Abstract][Full Text] [Related]
15. Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis.
Łączna M; Malinowski D; Paradowska-Gorycka A; Safranow K; Dziedziejko V; Pawlik A
Eur J Clin Pharmacol; 2021 Nov; 77(11):1673-1678. PubMed ID: 34160668
[TBL] [Abstract][Full Text] [Related]
16. Myelosuppressive and hepatotoxic potential of leflunomide and methotrexate combination in a rat model of rheumatoid arthritis.
Bilasy SE; Essawy SS; Mandour MF; Ali EA; Zaitone SA
Pharmacol Rep; 2015 Feb; 67(1):102-14. PubMed ID: 25560583
[TBL] [Abstract][Full Text] [Related]
17. The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide.
Dziedziejko V; Kurzawski M; Safranow K; Chlubek D; Pawlik A
Pharmacogenomics; 2011 Jan; 12(1):41-7. PubMed ID: 21174621
[TBL] [Abstract][Full Text] [Related]
18. Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2.
Han XM; Ouyang DS; Chen XP; Shu Y; Jiang CH; Tan ZR; Zhou HH
Br J Clin Pharmacol; 2002 Nov; 54(5):540-3. PubMed ID: 12445035
[TBL] [Abstract][Full Text] [Related]
19. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.
Pawlik A; Herczynska M; Kurzawski M; Safranow K; Dziedziejko V; Drozdzik M
Pharmacogenomics; 2009 Feb; 10(2):303-9. PubMed ID: 19207032
[TBL] [Abstract][Full Text] [Related]
20. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study.
Kiely PD; Johnson DM
Rheumatology (Oxford); 2002 Jun; 41(6):631-7. PubMed ID: 12048288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
